These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26757613)

  • 1. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
    Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabie A; Cheret A; Lahoulou R; Raffi F; Pugliese P;
    Infect Dis (Lond); 2016; 48(5):392-8. PubMed ID: 26757613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort.
    Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabié A; Cheret A; Lahoulou R; Raffi F; Pugliese P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19780. PubMed ID: 25397524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
    Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
    Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
    Gazzola L; Cicconi P; Ripamonti D; Di Filippo E; Gustinetti G; Di Biagio A; Marchetti G; Bini T; d'Arminio Monforte A
    HIV Clin Trials; 2014; 15(4):140-50. PubMed ID: 25143023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to an etravirine-containing regimen due to drug intolerance in clinical practice.
    Martín-Carbonero L; Moreno V; Ramírez-Olivenza G; Valencia E
    HIV Clin Trials; 2014; 15(2):57-61. PubMed ID: 24710919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
    Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
    Echeverría P; Bonjoch A; Puig J; Moltó J; Paredes R; Sirera G; Ornelas A; Pérez-Álvarez N; Clotet B; Negredo E
    PLoS One; 2014; 9(2):e84676. PubMed ID: 24503952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
    HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
    Ciaffi L; Cavassini M; Genne D; Delhumeau C; Spycher Elbes R; Hill A; Wandeler G; Fehr J; Stoeckle M; Schmid P; Hirschel B; Montecucco F; Calmy A;
    Eur J Clin Invest; 2015 Jul; 45(7):720-30. PubMed ID: 25989829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
    Vingerhoets J; Azijn H; Tambuyzer L; Dierynck I; De Meyer S; Rimsky L; Nijs S; De Smedt G; de Béthune MP; Picchio G
    AIDS Res Hum Retroviruses; 2010 Jun; 26(6):621-4. PubMed ID: 20507207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
    DeJesus E; Fätkenheuer G; Orrell C; Wang C; Jones J; Craig C; Tawadrous M; Heera J
    HIV Clin Trials; 2014; 15(5):209-17. PubMed ID: 25350959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
    Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
    HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Etravirine in first-line therapy].
    Garcés PA; Tena EV
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():12-20. PubMed ID: 20116623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.